Find, compare & contact
Alunacedase alfa
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Alunacedase alfa API 2416824-55-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Alunacedase alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Alunacedase alfa
- Synonyms:
- Recombinant Human Angiotensin-Converting Enzyme 2 , rhACE2
- Cas Number:
- 2416824-55-8
- DrugBank number:
- DB15736
- Unique Ingredient Identifier:
- FA2I4Z873U
General Description:
Alunacedase alfa, identified by CAS number 2416824-55-8, is a notable compound with significant therapeutic applications. Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Mechanism of Action:
Alunacedase alfa functions by: Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Alunacedase alfa belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Alunacedase alfa is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Carboxypeptidases, Enzymes, Enzymes and Coenzymes, Exopeptidases, Experimental Unapproved Treatments for COVID-19, Hydrolases, Peptide Hydrolases, Proteins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Alunacedase alfa is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
